Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
about
Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughterspETM: a penalized Exponential Tilt Model for analysis of correlated high-dimensional DNA methylation data.Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesisKey tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancerDNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.DNA methyltransferases, DNA damage repair, and cancerBase-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.Assessment of DNA methylation status in early stages of breast cancer development.HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation.Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survivalPromoter hypermethylation profiling of distant breast cancer metastases.Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis.Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes.PAX Genes in Cancer; Friends or Foes?Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases.DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer.PAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer.A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.Asymmetric Cancer Hallmarks in Breast Tumors on Different Sides of the BodyOncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplificationTranscriptional and epigenetic mechanisms of early cortical development: An examination of how Pax6 coordinates cortical development.High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring.DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expressionQuantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinomaPromoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.DNA methylation in ductal carcinoma in situ of the breast.Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors.Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity.DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) studyHigh-resolution array CGH and gene expression profiling of alveolar soft part sarcoma.Progression from ductal carcinoma in situ to invasive breast cancer: revisited.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7.Ductal carcinoma in situ - update on risk assessment and management.
P2860
Q27027009-90C37552-2B11-450C-9CF8-2C8EB7BC98E9Q31159752-19936FA2-2B49-43A4-BBC8-01A2CF7EAC2AQ33739319-7DF2458B-38C2-4A54-A621-62F1B4E9940DQ34084254-3657B493-58A5-4778-955C-825BBC35B65EQ34088277-89727BF4-FC46-40DD-A811-A6C37C3E4DCFQ34249360-7B4B1346-50C2-464B-9112-3B74E3B0D9D8Q34298096-982C6442-EAD2-4026-926D-ADB06F12D127Q34318280-AA49B662-74A3-4465-AB4F-748856BBAEE8Q34504432-5C9E35BE-0BD0-4A58-BABB-613C6A192A43Q34709370-8C7D2A90-0AEE-49D8-A6E1-3705FB8C386FQ34998465-04551A52-5EEA-4710-B8D7-DA4A7949DA3AQ35000210-34CB3E3C-3CB0-42C2-AA6C-72FE0AC9A20BQ35000317-7D498A62-E68C-4F52-BC5A-F9C4119F0272Q35533772-B7C19D8F-ED7E-46C3-953C-70FED942A78CQ35584026-8B97C379-B599-46C3-B6E3-06750785D0AAQ35651346-B7FC3DD6-8902-4CCF-8411-ABFFF98A4515Q35714437-E9F09FF5-8F75-4836-8C01-1CC18D5C57E7Q35846508-2E0702FA-B15C-4B92-A21A-A8EB2225F897Q35866022-253F2B5F-BD0C-4B53-B308-747295769AD5Q35888926-9D82F9A1-0891-4111-AF1A-2F0D953AA9FAQ35943149-D0EB6928-56DE-440C-BB31-AADA170F60FCQ36010918-456F94E2-FCB1-4FD7-A862-CA249BBB292DQ36069030-80E5CFF6-F434-479F-9EB8-1AA315D96844Q36147178-B4969BA8-262A-4B99-A989-DA850239709CQ36446768-F8CC16E0-675B-4A15-B938-C4D0E54DBD4AQ36606072-3C43B839-B9AD-4A10-924A-AEFE1ED9A396Q36768855-A2471963-0B32-4DF5-A909-2C5D4FD1941CQ36792134-F50FFBEB-8FB6-4242-ABF0-A0CDCC0BB6B2Q36797506-8975EC97-B3CF-4DD8-A9EC-010810DAF70CQ36825828-AFB1D2E0-8D02-4B01-B86E-C40D36B6DEC7Q36924432-81C89653-5CAC-4048-8226-68EFBC2F4C02Q36998647-5BDFFED7-CA88-474A-B38B-56B82E597C4FQ37148924-1638A192-B446-4F67-8E70-95CB9545D3D4Q37219845-3B4E5673-AF7A-4902-B799-F6699F42B5B8Q37308097-08AF843B-DA67-498E-8DAA-CCA3A5AA6E77Q37656149-D97B9CE6-D04C-4D74-A49F-8599BAD118DDQ38124521-04296BD5-4A58-4E38-BBEB-548068177C7EQ38242086-EC343DB0-4796-4F04-A0A0-6D9E4DC1B44CQ38480346-8BEDA673-3C84-4FE2-89F2-A34AA5157439Q38696796-71E10D01-FB1E-41B9-90C7-AB284BC04401
P2860
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@ast
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@en
type
label
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@ast
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@en
prefLabel
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@ast
Frequent promoter hypermethyla ...... tu and invasive breast cancer.
@en
P356
P1476
Frequent promoter hypermethyla ...... itu and invasive breast cancer
@en
P2093
Anoek H J Verschuur-Maes
Paul J van Diest
P304
P356
10.1002/PATH.2930
P577
2011-06-27T00:00:00Z